Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ras protein

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    53 result(s) found for: Ras protein. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2019-002834-35 Sponsor Protocol Number: PARERE Start Date*: 2020-09-24
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST
    Full Title: Randomized phase II study of PAnitumumab REchallenge followed by REgorafenib versus the reverse sequence in RAS and BRAF WILD-TYPE chemorefractory metastatic colorectal cancer patients.
    Medical condition: RAS and BRAF wild-type chemorefractory metastatic colorectal cancer patients
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003243-21 Sponsor Protocol Number: XL092-303 Start Date*: 2022-10-06
    Sponsor Name:Exelixis, Inc.
    Full Title: A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
    Medical condition: Metastatic colorectal cancer (CRC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004176-18 Sponsor Protocol Number: CHK01-02 Start Date*: 2021-06-21
    Sponsor Name:Chinook Therapeutics U.S., Inc.
    Full Title: A Phase 2, Open-Label, Basket Study of Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study)
    Medical condition: Proteinuric glomerular diseases, including: Immunoglobulin A nephropathy (IgAN) (with UPCR 0.5 to <1.0 g/g) Focal segmental glomerulosclerosis (FSGS) Alport Syndrome Diabetes kidney disease (DKD) (...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002935-14 Sponsor Protocol Number: EMPRA Start Date*: 2016-11-22
    Sponsor Name:Medical University of Vienna, Internal Medicine III, Clinical Div. of Nephrology and Dialysis
    Full Title: Effect of empagliflozin on the renin-angiotensin system in patients with chronic kidney disease with and without type 2 diabetes
    Medical condition: Chronic kidney disease with and without type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10076411 Chronic kidney disease stage 4 LLT
    20.0 100000004857 10076410 Chronic kidney disease stage 3 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001431-27 Sponsor Protocol Number: CovidVal01 Start Date*: 2020-06-05
    Sponsor Name:Klinikum St. Georg gGmbH
    Full Title: Treatment of Sars-CoV2 infections (Covid-19) in patients without or with chronic kidney disease (CKD) with valsartan vs placebo, a three-armed randomized, partly blinded trial
    Medical condition: Sars-Cov2 infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-000845-64 Sponsor Protocol Number: CCR4085 Start Date*: 2014-12-17
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: A multicentre randomised phase II study of aflibercept plus chemotherapy in patients with colorectal liver-only metastases deemed to be inoperable or unsuitable for upfront liver resection
    Medical condition: colorectal cancer with liver metastases
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001441-14 Sponsor Protocol Number: IFOM-CPT002/2018/PO001 Start Date*: 2018-10-29
    Sponsor Name:IFOM - Istituto FIRC di Oncologia Molecolare - Milano
    Full Title: PEMBROLIZUMAB IN MMR-PROFICIENT METASTATIC COLORECTAL CANCER PHARMACOLOGICALLY PRIMED TO TRIGGER DYNAMIC HYPERMUTATION STATUS
    Medical condition: RAS mutated metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-004281-71 Sponsor Protocol Number: 20070509 Start Date*: 2009-02-10
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously ...
    Medical condition: Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003084-26 Sponsor Protocol Number: CHK0101 Start Date*: 2021-04-08
    Sponsor Name:Chinook Therapeutics U.S., Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study)
    Medical condition: Immunoglobulin A Nephropathy (IgAN)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) CZ (Completed) IE (Completed) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-005386-35 Sponsor Protocol Number: GI-4000-02 Start Date*: 2008-10-07
    Sponsor Name:GlobeImmune, Inc.
    Full Title: A Phase 2 Double-Blind, Placebo Controlled, Multi-center Adjuvant Trial of the Efficacy, Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces cerevisiae Expressing Mutant...
    Medical condition: Pancreatic Cancer, post resection R0/R1 status, with tumor sequence confirmation of Ras mutations
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10033575 Pancreas cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001713-14 Sponsor Protocol Number: PROCEED Start Date*: 2011-05-18
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: A PROSPECTIVE, RANDOMIZED, CROSS-OVER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE ANTIPROTEINURIC EFFECT OF SELECTIVE VITAMIN D RECEPTOR ACTIVATION BY PARICALCITOL IN TYPE 2 DIABETES PATI...
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005416-26 Sponsor Protocol Number: ANSWER Start Date*: 2014-06-06
    Sponsor Name:Mario Negri Institute
    Full Title: A Prospective, Randomized, Open, Blinded Endpoint (PROBE), Clinical Trial to Assess The Renal and Humoral Effects of Sevelamer Carbonate in Patients with Chronic Kidney Disease and Residual Protein...
    Medical condition: Chronic Kidney Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004709-42 Sponsor Protocol Number: NL63792.099.17 Start Date*: 2018-04-24
    Sponsor Name:Martini Hospital
    Full Title: An open-label randomised cross-over study to evaluate the albuminuria lowering effect of dapagliflozin, exenatide and their combination in patients with type 2 diabetes
    Medical condition: Type 2 diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003220-19 Sponsor Protocol Number: BO18602 Start Date*: 2005-12-29
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A multicentre, open-label, randomized, phase III study to evaluate the efficacy of Tarceva™ or comparator Alimta® (pemetrexed) or Taxotere® (docetaxel) in patients with histologically documented, a...
    Medical condition: Advanced (stage IIIB or IV) non-small cell lung cancer (NSCLC) previously treated with a platinum-based chemotherapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) SI (Completed) GB (Completed) BE (Completed) LT (Completed) SK (Completed) HU (Completed) AT (Prematurely Ended) DK (Completed) PT (Completed) CZ (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002241-39 Sponsor Protocol Number: BO 18192 Start Date*: 2005-11-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A multicentre, double-blind randomised, phase III study to evaluate the efficacy of Tarceva or placebo following 4 cycles of platinum-based chemotherapy in patients with histologically documented a...
    Medical condition: Advanced (stage IIIB or IV) NSCLC previously treated with 4 cycles of a platinum-based chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) SI (Completed) GB (Completed) AT (Completed) LT (Completed) SK (Completed) PT (Prematurely Ended) DE (Completed) DK (Completed) CZ (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003402-40 Sponsor Protocol Number: XL184-401 Start Date*: 2015-06-16
    Sponsor Name:Exelixis, Inc.
    Full Title: A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients
    Medical condition: Progressive Metastatic Medullary Thyroid Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027105 Medullary thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) SE (Completed) ES (Ongoing) FR (Completed) PL (Trial now transitioned) HU (Trial now transitioned) HR (Trial now transitioned) IT (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000835-30 Sponsor Protocol Number: MONET Start Date*: 2021-10-12
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: RESCUE THERAPY WITH THE HUMAN ANTI-CD38 ANTIBODY MOR202 (FELZARTAMAB) IN PATIENTS WITH MEMBRANOUS NEPHROPATHY WHO FAILED ANTI-CD20 TARGETED THERAPY: A PILOT, PROOF-OF-CONCEPT STUDY
    Medical condition: Membranous Nephropathy who Failed Anti-CD20 Target Therapy.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001426-22 Sponsor Protocol Number: ALXN2050-NEPH-201 Start Date*: 2022-05-30
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunogl...
    Medical condition: Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001955-38 Sponsor Protocol Number: TTD-12-03 Start Date*: 2012-07-19
    Sponsor Name:Grupo de Tratamiento de los Tumores Digestivos (TTD)
    Full Title: Open label Phase II study of Folfiri + Panitumumab using ultra-selection technology with next generation high sensitivity genotyping of patients with stage IV colorectal cancer refractory to irinot...
    Medical condition: Metastatic colorectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000726-10 Sponsor Protocol Number: ADAPT Start Date*: 2021-06-23
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: Evaluating the short-term renal and systemic effects of Dapagliflozin in non-diabetic patients with stage IV CKD at risk of ESKD because of severe renal insufficiency and persistent proteinuria: A ...
    Medical condition: Non-diabetic stage IV Chronic Kidney Disease (CKD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10009119 Chronic renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Nov 22 01:48:41 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA